AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

144.380

+3.3902.40%

Volume:675.80K

Turnover:96.74M

Market Cap:70.05B

PE:35.13

High:144.830

Open:141.480

Low:140.320

Close:140.990

52wk High:269.118

52wk Low:133.350

Shares:485.15M

Float Shares:483.95M

Volume Ratio:0.37

T/O Rate:0.14%

Dividend:4.20

Dividend Rate:2.91%

EPS(TTM):4.110

EPS(LYR):8.872

ROE:6.66%

ROA:6.58%

PB:2.61

PE(LYR):16.27

Loading ...

Overview Company News Filings

CSL Ltd - Paul Mckenzie Will Retire as Managing Director

THOMSON REUTERS

CSL Ltd-Paul Mckenzie Retires, Gordon Naylor Appointed Interim CEO

THOMSON REUTERS

BUZZ-CSL's Memo deal signals new R&D philosophy, Jefferies says

BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology

Memo Therapeutics Ag Enters Into a Collaboration and Option Agreement With CSL for Development of Recombinant Polyclonal Igg Technology

THOMSON REUTERS

Memo Therapeutics Ag: Agreement Includes R&D Funding for Exploratory Work, Technology Access

THOMSON REUTERS

Memo Therapeutics Ag: Co Will Develop Recombinant Polyclonal Igg Using Dropzylla Platform to Clone Antibody Repertoires,Express Antibodies

THOMSON REUTERS

Seqirus Spin-off Pause and Flu Demand Concerns Could Be A Game Changer For CSL (ASX:CSL)

Simply Wall St.

DIARY-Australia, New Zealand corporate earnings week ahead

Haemonetics meldet Free Cash Flow im dritten Quartal 2026 von 165,42 Mio. USD mit Anstieg um 233 Prozent

Assessing CSL’s (ASX:CSL) Valuation As Results And Dividend Expectations Confront Recent Growth And Regulatory Headwinds

Simply Wall St.

Cochin Shipyard Limited Invites Global Expressions of Interest for Empanelment of Territorial Representatives

Does CSL (ASX:CSL) Offer Value After A 34% One Year Share Price Fall

Simply Wall St.

William Blair Initiates Coverage on Carlisle Companies With Market Perform

MT Newswires Live

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

How CSL’s ADR Switch and Plasma Pressures At CSL (ASX:CSL) Has Changed Its Investment Story

Simply Wall St.

BUZZ-Jefferies sees low risk of earnings impact for CSL from potential US regulatory review

Assessing CSL (ASX:CSL) Valuation As Half Year Results And Seqirus Uncertainty Approach

Simply Wall St.

The Bull Case For Carlisle Companies (CSL) Could Change Following Its Vision 2030 Acquisition Drive – Learn Why

Simply Wall St.

How Investors May Respond To CSL (ASX:CSL) After RBC Upgrade Amid Seqirus Spin-Off Pause

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSL.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":144.38,"timestamp":1774501678216,"preClose":140.99,"halted":0,"volume":675801,"delay":0,"changeRate":0.024044258458046572,"nameEN":"CSL LIMITED","floatShares":483950454,"shares":485151394,"eps":4.109668661618413,"marketStatus":"CSPA","change":3.39,"latestTime":"03-26 16:10:11 AEDT","open":141.48,"high":144.83,"low":140.32,"amount":96739845,"amplitude":0.031988,"askPrice":129.95,"askSize":452,"bidPrice":164.59,"bidSize":129,"shortable":3,"etf":0,"ttmEps":4.109668661618413,"tradingStatus":3,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774566000000},"marketStatusCode":14,"adr":0,"exchange":"ASX","adjPreClose":140.99,"dividendRate":0.028696,"openAndCloseTimeList":[[1774479600000,1774501200000]],"volumeRatio":0.370569,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":140.99,"auctionPrice":144.27,"auctionVolume":455569,"auctionTime":1774501809374,"referencePrice":144.38,"referenceTime":1774501678216,"auction":3,"marketStatus":"盘后竞价","timestamp":1774501809374}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":483950454,"roa":"6.58%","roe":"6.66%","lyrEps":8.872309,"volumeRatio":0.370569,"shares":485151394,"dividePrice":4.198889,"high":144.83,"amplitude":0.031988,"preClose":140.99,"low":140.32,"week52Low":133.35,"pbRate":"2.61","psRate":"3.16","week52High":269.118,"institutionHeld":0,"latestPrice":144.38,"committee":-0.555938,"eps":4.109668661618413,"divideRate":0.029082,"volume":675801,"delay":0,"ttmEps":4.109668661618413,"open":141.48,"prevYearClose":170.408,"prevWeekClose":138.5,"prevMonthClose":144.854,"prevQuarterClose":170.408,"fiveDayClose":134.62,"twentyDayClose":144.124,"sixtyDayClose":170.181,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":4,"dividendGrowthRate":0.11620984529927163,"fiveYearAvgDividendRate":0.013228653048611719},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"},{"date":"2025-08-19","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755561600000,"name":null,"time":"","dateTimestamp":1755525600000,"actualEps":null},{"date":"2025-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2025-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-09","payableDate":"2025-03-11","currency":"USD","dateTimestamp":1741525200000,"payDate":"2025-04-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610697978","title":"CSL Ltd - Paul Mckenzie Will Retire as Managing Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2610697978","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610697978?lang=en_us&edition=fundamental","pubTime":"2026-02-10 13:05","pubTimestamp":1770699956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUE12082B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CSL.AU","BK7508","BK7511","BK7501"],"gpt_icon":0},{"id":"2610697973","title":"CSL Ltd-Paul Mckenzie Retires, Gordon Naylor Appointed Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2610697973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610697973?lang=en_us&edition=fundamental","pubTime":"2026-02-10 13:05","pubTimestamp":1770699956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUE12082B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2610683756","title":"BUZZ-CSL's Memo deal signals new R&D philosophy, Jefferies says","url":"https://stock-news.laohu8.com/highlight/detail?id=2610683756","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610683756?lang=en_us&edition=fundamental","pubTime":"2026-02-10 02:40","pubTimestamp":1770662451,"startTime":"0","endTime":"0","summary":"BUZZ-CSL's Memo deal signals new R&D philosophy, Jefferies says** Jefferies says Australia's CSL CSL.AX sees its new agreement with Switzerland-based Memo Therapeutics as \"evidence\" that the biotech major is now focusing on development by buying assets into its pipeline** Memo on Monday said it entered into a collaboration and option agreement with CSL for development of recombinant polyclonal IgG technology, a method used to clone antibodies** Jefferies notes CSL is looking to reenergise its research function in the longer term; however, flags it will likely take time, given the nature of R&D** Brokerage adds Memo deal could help with CSL's product growth in the medium term, following co's VarmX deal last year** CSL up 4.5% so far this year, as of last close","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nL4N3Z51TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2610637722","title":"BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637722","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610637722?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:18","pubTimestamp":1770639539,"startTime":"0","endTime":"0","summary":"BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg TechnologyFeb 9 (Reuters) - CSL Ltd CSL.AX:MEMO THERAPEUTICS AG ENTER","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z515R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7511","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2610463745","title":"Memo Therapeutics Ag Enters Into a Collaboration and Option Agreement With CSL for Development of Recombinant Polyclonal Igg Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2610463745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610463745?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:09","pubTimestamp":1770638958,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z515R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2610374296","title":"Memo Therapeutics Ag: Agreement Includes R&D Funding for Exploratory Work, Technology Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2610374296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610374296?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:09","pubTimestamp":1770638958,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z515R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2610266637","title":"Memo Therapeutics Ag: Co Will Develop Recombinant Polyclonal Igg Using Dropzylla Platform to Clone Antibody Repertoires,Express Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2610266637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610266637?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:09","pubTimestamp":1770638958,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z515R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CSL.AU","BK7508","BK7511","BK7501"],"gpt_icon":0},{"id":"2609446795","title":"Seqirus Spin-off Pause and Flu Demand Concerns Could Be A Game Changer For CSL (ASX:CSL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609446795","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609446795?lang=en_us&edition=fundamental","pubTime":"2026-02-07 12:21","pubTimestamp":1770438096,"startTime":"0","endTime":"0","summary":"In recent weeks, CSL has been in focus as investors look back on its February 11 half-year results and interim dividend announcement, following earlier cuts to its fiscal 2026 growth outlook and a pause to the planned Seqirus vaccines spin-off after weaker US flu vaccination rates.\nAt the same time, CSL has faced regulatory scrutiny over Tavneos data in Europe and tougher competition for its Vifor iron products, sharpening attention on how well the group can balance growth ambitions with...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/seqirus-spin-off-pause-and-flu-demand-concerns-could-be-a-ga","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/seqirus-spin-off-pause-and-flu-demand-concerns-could-be-a-ga","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","CSL","BK4543","BK7067","LU1169589451.USD","BK7511","BK7501","AI","CSL.AU","BK4585","BK4086","SGXZ23171101.USD","LU0728928796.USD","BK4528","BK7508","LU1169590202.USD","BK4588","BK4587","SG9999004303.SGD","BK4551"],"gpt_icon":0},{"id":"2609653957","title":"DIARY-Australia, New Zealand corporate earnings week ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2609653957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609653957?lang=en_us&edition=fundamental","pubTime":"2026-02-06 09:00","pubTimestamp":1770339600,"startTime":"0","endTime":"0","summary":"DIARY-Australia, New Zealand corporate earnings week aheadFeb 6 (Reuters) - Diary of Australia and New Zealand (.AXJO, .NZ50) corporate earnings for the week ahead AUSTRALIA & NEW ZEALAND EARNINGS Sta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4N3Z11DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7062","BK7006","NCK.AU","ORG.AU","BK4135","HDN.AU","CLW.AU","GQG.AU","BK7119","CIP.AU","BK7007","BK7508","IAG.AU","TPW.AU","BK7511","BK7112","S32.AU","NST.AU","BK7120","BK7094","ARF.AU","SGH.AU","COH.AU","CSL.AU","BK4011","AGL.AU","BK7005","BK7501","BK7507","BRG.AU","PME.AU","BK7130","WBC.AU","CBA.AU","BK7067","GQPIL","BK7095","EVN.AU","BK7136","BK7162","JHX","BK7165","BK7034","BK7099","BK7135","BK7506","BK7031","AMP.AU","BK7107","BK7049"],"gpt_icon":0},{"id":"2609837610","title":"Haemonetics meldet Free Cash Flow im dritten Quartal 2026 von 165,42 Mio. USD mit Anstieg um 233 Prozent","url":"https://stock-news.laohu8.com/highlight/detail?id=2609837610","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609837610?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:02","pubTimestamp":1770289358,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL5JhlcD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL.AU","IE0034390439.USD","IE00BLDYK493.USD","BK4198","IE00B19Z6F94.USD","LU0106261612.USD","HAE","LU0012050646.USD","LU0205193047.USD","LU1169590202.USD","BK7508","LU1169589451.USD","LU0205194284.USD","IE00B64QTZ34.USD","BK7511","BK7501"],"gpt_icon":0},{"id":"2609434698","title":"Assessing CSL’s (ASX:CSL) Valuation As Results And Dividend Expectations Confront Recent Growth And Regulatory Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2609434698","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609434698?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:47","pubTimestamp":1770248822,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is back in focus after its share price reacted to fresh anticipation around the upcoming half-year results and interim dividend, with recent guidance changes and regulatory reviews shaping expectations.\nSee our latest analysis for CSL.\nAt A$181.7, CSL’s recent 1 month share price return of 5.36% and 1 day gain of 2.02% suggest short term momentum is building again, although the 1 year total shareholder return of 31.46% decline shows longer term holders are still sitting on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-asxcsl-valuation-as-results-and-dividend-expe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-asxcsl-valuation-as-results-and-dividend-expe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7511","BK7508","CSL.AU","BK4086","BK7501","CSL","LU0728928796.USD","LU1169590202.USD","SG9999004303.SGD","SGXZ23171101.USD","BK7067","LU1169589451.USD"],"gpt_icon":0},{"id":"2608085408","title":"Cochin Shipyard Limited Invites Global Expressions of Interest for Empanelment of Territorial Representatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2608085408","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608085408?lang=en_us&edition=fundamental","pubTime":"2026-02-02 17:20","pubTimestamp":1770024000,"startTime":"0","endTime":"0","summary":"KOCHI, India, Feb. 2, 2026 /PRNewswire/ -- Cochin Shipyard Limited , a premier Government of India enterprise, has invited Expressions of Interest  from internationally reputed companies, firms, or agencies for empanelment as Territorial Representatives for ship repair and refit projects across key global markets.This initiative is part of CSL's strategic efforts to strengthen its global outreach and deliver world-class ship repair, refit, and conversion services to international customers. The empanelled Territorial Representatives will support CSL by leveraging local market intelligence, promoting its ship repair capabilities, and facilitating business development within their respective regions.Commenting on the initiative, a CSL spokesperson said that this empanelment initiative aligns with their long-term vision to enhance Cochin Shipyard's global footprint and provide customers worldwide with seamless access to CSL's ship repair and refit expertise","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/cochin-shipyard-limited-invites-global-expressions-of-interest-for-empanelment-of-territorial-representatives-302676101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4211","SG9999004303.SGD","BK7511","CSL.AU","CSL","BK4086","BK7508","LU0728928796.USD","BK7501","LU1169590202.USD","SGXZ23171101.USD","BK7067","TBNK","BK4195"],"gpt_icon":0},{"id":"2608077467","title":"Does CSL (ASX:CSL) Offer Value After A 34% One Year Share Price Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077467","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608077467?lang=en_us&edition=fundamental","pubTime":"2026-01-31 23:31","pubTimestamp":1769873511,"startTime":"0","endTime":"0","summary":"If you are wondering whether CSL is priced attractively right now, its recent share performance and current valuation profile raise some timely questions.\nCSL last closed at A$181.42, with returns of 1.0% over 7 days and 5.1% over 30 days, while the 1 year and 3 year returns of a 34.0% decline and 39.5% decline contrast with a 5.5% gain year to date.\nRecent coverage around CSL has focused on its position as a major Australian healthcare stock and ongoing interest from investors assessing how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-offer-value-after-a-34-one-year-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-offer-value-after-a-34-one-year-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7501","BK7511","CSL.AU","LU1169589451.USD","DCF","CSL","SG9999004303.SGD","BK4086","SGXZ23171101.USD","BK7067","LU1169590202.USD","LU0728928796.USD"],"gpt_icon":0},{"id":"2607010424","title":"William Blair Initiates Coverage on Carlisle Companies With Market Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=2607010424","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607010424?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:20","pubTimestamp":1769775602,"startTime":"0","endTime":"0","summary":"Carlisle Companies (CSL) has an average rating of overweight and mean price target of $371.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGXZ23171101.USD","LU0728928796.USD","BK7511","BK7067","BK4086","CSL","LU1169590202.USD","BK7508","LU1169589451.USD","BK7501","CSL.AU","SG9999004303.SGD"],"gpt_icon":0},{"id":"2607801702","title":"FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2607801702","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607801702?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:07","pubTimestamp":1769774827,"startTime":"0","endTime":"0","summary":"FACTBOX-Global drugmakers rush to boost US presence as tariff threat loomsChanges dateline, adds Eli Lilly details in paragraph 11. Jan 30  - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:Pfizer PFE.N Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL4N3YV11K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880407132.USD","LU0784383803.USD","LU0823416689.USD","IE00B19Z9P08.USD","LU0823399737.USD","LU0882574139.USD","LU1221951046.USD","LU2471134879.HKD","LU2129689514.USD","LU0310800379.SGD","BK7501","LU1496350171.SGD","LU1267930490.SGD","LU1585245621.USD","SG9999014898.SGD","SG9999015952.SGD","LU0114720955.EUR","IE00B3T34201.USD","SGXZ81514606.USD","LU2237443465.HKD","IE00B1BXHZ80.USD","LU1232071149.USD","LU0238689110.USD","LU0321505868.SGD","IE000M9KFDE8.USD","LU0211327993.USD","SG9999015341.SGD","LU0225771236.USD","LU0575583348.USD","LU0211326755.USD","BK4599","LU0980610538.SGD","LU0321505439.SGD","IE00B7SZLL34.SGD","LU1170363599.USD","LU2746668974.SGD","LU2089984988.USD","LU1078025761.USD","LU0553294199.USD","BIIB","LU1720051017.SGD","LU0857590862.USD","IE00BVYPNV92.GBP","LU0061475181.USD","LU0265550946.USD","SG9999014906.USD","LU0949170772.SGD","LU0354030438.USD","LU2168564065.EUR","LU2168564222.USD","LU2539964713.USD","LU0234570918.USD","LU1883839398.USD","LU1153584641.USD","LU0827474353.SGD","IE00BKPKM643.USD","LU2111349929.HKD","LU2456880835.USD","LU1481600234.SGD","LU1291159041.SGD","LU1988902786.USD","LU2237443978.SGD","LU1430594728.SGD","LU2168564495.EUR","BK4588","LU0345770993.USD","LU0965509010.AUD","LU2361044865.SGD","LU0526926950.USD","LU0985320562.USD","LU2491049909.HKD","LU0738911758.USD","LU1059921491.USD","GILD","LU1548497426.USD","LU0708994859.HKD","LU0868494617.USD","LU0499090636.EUR","LU1066051811.HKD","IE00BJJMRY28.SGD","IE00BVYPNW00.USD","LU1718418525.SGD","SG9999014542.SGD","BK4568","LU2505996509.AUD","MRK","LU1066051498.USD","LU2357305700.SGD","IE0005OL40V9.USD","IE00BFTCPJ56.SGD","IE0004445239.USD","SG9999014559.SGD","LU1674673691.USD","LU1066051225.USD","LU2125154778.USD","LU1104425308.USD","LU1032466523.USD","LU1093756325.SGD","LU2237438978.USD","LU2089283258.USD","LU0289739699.SGD","LU2750360641.GBP","LU1551013342.USD","LU0471298694.HKD","LU2242646821.SGD","SGXZ31699556.SGD","LU2552382058.USD","IE00BKPKM429.USD","LU0823434583.USD","LU0210536198.USD","BK4585","LU0306806265.USD","BK5011","LU2361044949.HKD","GSK","LU1699723380.USD","LU0106261372.USD","LU0345777147.USD","IE00BFSS8Q28.SGD","IE00B4R5TH58.HKD","BK4504","LU0234572021.USD","LU0784385170.HKD","CSL.AU","LU0787776722.HKD","LU0097036916.USD","LU0943347566.SGD","IE00B4JS1V06.HKD","IE00B19Z3581.USD","LU0965508806.USD","LU1035773651.USD","IE00BGHQF631.EUR","LU2237443549.SGD","LU0545039389.USD","SG9999014914.USD","LU0472753341.HKD","LU0969580561.USD","LU2023250504.SGD","LU2324357040.USD","LU0345770308.USD","LU0889565916.HKD","SG9999001440.SGD","LU0109391861.USD","LU1983299246.USD","LU0029864427.USD","IE0034235303.USD","LU2360106947.USD","LU0225284248.USD","LU1116320737.USD","LU0345769631.USD","BK4566","03165","LU1093756168.USD","LU0972486137.USD","IE00BKVL7J92.USD","LU0640476718.USD","LU2750360997.AUD","LU1037948897.HKD","LU1481599808.USD","LU0289961442.SGD","LU1267930813.SGD","LU1487256676.USD","LU1061106388.HKD","LU1074936037.SGD","AZN","LU1037948541.HKD","LU2129689431.USD","IE00BDGV0183.EUR","LU1023059063.AUD","LU0057025933.USD","SG9999018857.SGD","LU2265009873.SGD","LU0171293334.USD","SG9999001176.SGD","LU1201861249.SGD","LU2023251221.USD","LU0963555726.SGD","SNY","IE00BWXC8680.SGD","LU0960981461.USD","LU2242652126.USD","LU1989772923.USD","LU0256863902.USD","LU1551013425.SGD","LU1084165304.USD","LU2746668461.USD","LU0070302665.USD","IE00B42XCP33.USD","LU1066053197.SGD","PFE","LU0289739343.SGD","LU1162221912.USD","LU2271345857.HKD","LU2236285917.USD","LU2023250843.SGD","LU2168563687.JPY","LU2360032135.SGD","BK4583","BK4532","AMGN","LU2592432038.USD","LU2471134952.CNY","BK4592","SG9999015945.SGD","LU0208291251.USD","LU1221951129.SGD","LU0795875169.SGD","LU0198837287.USD","IE00BFSS7M15.SGD","LU0211331839.USD","BK7511","IE00B3PB1722.GBP","LU1839511570.USD","SGXZ51526630.SGD","LU0096364046.USD","LU0047473722.SGD","LU0965509283.SGD","LU0417517546.SGD","LU1868837300.USD","LU1934455863.HKD","LU2430703178.SGD","IE00B894F039.SGD","LU1323610961.USD","LU2125154935.USD","LU1244550494.USD","IE00BN8TJ469.HKD","LU1267930227.SGD","LU1127390331.HKD","BK7508","LU0265550359.USD","LU1003076772.USD","LU0122379950.USD","LU1571399168.USD","LU0320765992.SGD","LU0985481810.HKD","LU2063271972.USD","LU2211815571.USD","LU0823434740.USD","LU0912757837.SGD","LU1051770623.HKD","LU0079474960.USD","LU0306807586.USD","LU0889566641.SGD","LU2430703251.USD","LU1935042991.SGD","LU1732799900.SGD","LU2108987350.USD","LU2237443382.USD","LU2168564149.EUR","SGXZ99366536.SGD","LU1720051108.HKD","SG9999015358.SGD","LU2491050071.SGD","LU1929549753.HKD","LU0820561818.USD","LU2237443622.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1989771016.USD","SG9999013999.USD","SGXZ57979304.SGD","LU2602419157.SGD","IE00BLSP4239.USD","LU0354030511.USD","LU1301847155.USD","LU0784385840.USD","LU1035775433.USD","LU2112291526.USD","LU2133065610.SGD","BK4139","LU0672654240.SGD","IE00B775H168.HKD","LU2417539215.USD","LU1196500208.SGD","LU2028103732.USD","SG9999015986.USD","LU0964806797.USD","LU1804176565.USD","LU2087625088.SGD","LU0310800965.SGD","LU0557290698.USD","LU1674673428.USD","SG9999011175.SGD","LU2462157665.USD","LU0047473722.EUR","LU1015430645.USD","LU1064131342.USD","LU0128525929.USD","LU2091194634.USD","LU2279689827.SGD","SG9999002232.USD","BK4559","LU0920840948.USD","LU2552382215.SGD","LU0661504455.SGD","LU0011850046.USD","LU0683600562.USD","LU2237443895.HKD","LU0353189763.USD","LU1732800096.USD","LU0203201768.USD","IE0002141913.USD","LU0795875086.SGD","LU0511384066.AUD","LU1069347547.HKD","LU1974910355.USD","LU0077335932.USD","LU0385154629.USD","LU2347655156.SGD","LU2293690249.USD","LU0310799852.SGD","LU0949170426.SGD","LU2264538146.SGD","SG9999014567.USD","LU1941712348.USD","IE0034235188.USD","SG9999018865.SGD","SG9999002224.SGD","LU1712237335.SGD","SG9999017495.SGD","LU0353189680.USD","LU0784384876.USD","JNJ","LU2491050154.USD","LU0432979614.USD","LU1894683264.USD","LU2114397693.USD","RHHBY","LU1019634622.SGD","SG9999015978.USD","LU1003077747.HKD","LU0861579265.USD","BK4578","LU0689472784.USD","IE00BJLML261.HKD","LU2293690082.USD","LU0170899867.USD","SG9999014880.SGD","IE0004445015.USD","LU1623119135.USD","IE0002270589.USD","LU0203202063.USD","LU0496365809.HKD","LU1057294990.SGD","BK4533","LU1267930730.SGD","LU0006306889.USD","LU1267930573.SGD","LU0477156953.USD","LU0058720904.USD","LU0128525689.USD","IE00BK4W5L77.USD","LU1868836591.USD","LU0158827781.USD","SG9999003800.SGD","LU0323591593.USD","LU1880407215.USD","LU0889565080.SGD","BK4516","LU2468319806.SGD","IE00BZ1G4Q59.USD","LU0130102774.USD","IE00BLSP4452.SGD","LU0203347892.USD","LU1868836914.USD","LU0070217475.USD","LU2361045086.USD","LU0689626769.HKD","GB00BDT5M118.USD","LU1894683348.USD","IE00B1XK9C88.USD","LU1064927863.SGD","LU1868837136.USD","LU2471134523.USD","LU0920783379.SGD","LU0345769128.USD","LU2896262040.SGD","LU0648001328.SGD","LU2106854487.HKD","LU1868836757.USD","IE00BBT3K403.USD","LU1116320901.HKD","LU0211326839.USD","BK4581","NVS","LU0820561909.HKD","LU0109394709.USD","BK4007","LU0757432116.USD","LU0052756011.USD","LU0130517989.USD","LU1069344957.HKD","LU0882574055.USD","LU1261432733.SGD","IE00BKDWB100.SGD","LU0471298777.SGD","LU0203345920.USD","BK7067","LU0124676726.USD","LU2471134796.USD","SG9999014575.USD","LU1506573853.SGD","LU0640478417.SGD","BK4534","LU1366192091.USD","LU0786609619.USD","LU1934455194.USD","IE00BN29S564.USD","IE00BK4W5M84.HKD","LU0211328371.USD","LU1941712264.USD","LU0320765646.SGD","LU0316494557.USD","LU1917777945.USD","IE00B7KXQ091.USD","LU1019632923.USD","LU1244550221.USD","LU2089284900.SGD","LU0094547139.USD","LU2552382132.HKD","IE00BJJMRX11.SGD","LU1989772840.SGD","LU0345777659.USD","LU2087621335.USD","LU0957799991.USD","IE00BSNM7G36.USD","LU1496350502.SGD","LU1778281490.HKD","LLY","LU0997586432.USD","LU0965509101.SGD","LU0266013472.USD","BK4550","LU1119994496.HKD","IE00BFXG1179.USD","LU0320765489.SGD","LU0069063385.USD","LU2461242641.AUD","LU0466842654.USD","LU0320765059.SGD","ABBV","LU2129689605.HKD","LU0098860793.USD","IE00B2B36J28.USD","LU0792757196.USD","LU0456855351.SGD","LU1032955483.USD","LU1244550577.SGD","LU0158827948.USD","LU1914381329.SGD","IE0009355771.USD","LU0225283273.USD","LU0256863811.USD","SG9999001176.USD","IE00B19Z3B42.SGD","LU0976567544.SGD","LU1934455277.USD","LU2430703095.HKD","IE00B19Z9Z06.USD","LU1280957306.USD","LU1153585028.USD","04332","LU0708995401.HKD","LU2505996681.GBP","LU1814569148.SGD"],"gpt_icon":1},{"id":"2607046165","title":"How CSL’s ADR Switch and Plasma Pressures At CSL (ASX:CSL) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046165","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607046165?lang=en_us&edition=fundamental","pubTime":"2026-01-30 17:31","pubTimestamp":1769765485,"startTime":"0","endTime":"0","summary":"Deutsche Bank has been appointed as the successor depositary bank for CSL Limited’s sponsored American Depositary Receipt program, effective 27 January 2026, while investors also await the company’s half-year results and interim dividend announcement on 11 February.\nThis comes after CSL cut its profit forecast, postponed the planned Seqirus vaccine spin-off, and faced pressure from weaker U.S. flu vaccination rates and cost challenges in its plasma therapies business.\nWe’ll now examine how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-csls-adr-switch-and-plasma-pressures-at-csl-asxcsl-has-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-csls-adr-switch-and-plasma-pressures-at-csl-asxcsl-has-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756325.SGD","BK4513","LU0728928796.USD","LU1093756168.USD","BK7511","BK4116","BK7508","LU1169589451.USD","SWCH","CSL.AU","LU1169590202.USD","BK7501","SG9999004303.SGD","BK7067","BK4086","CSL","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2607747214","title":"BUZZ-Jefferies sees low risk of earnings impact for CSL from potential US regulatory review","url":"https://stock-news.laohu8.com/highlight/detail?id=2607747214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607747214?lang=en_us&edition=fundamental","pubTime":"2026-01-29 04:52","pubTimestamp":1769633577,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies sees low risk of earnings impact for CSL from potential US regulatory review** Jefferies expects minimal risk of meaningful earnings impact for CSL CSL.AX as various U.S. regulatory reviews including CMS programs are undertaken** Brokerage says there is ongoing lack of regulatory focus on plasma - key product for CSL - compared with other drug categories** Adds plasma industry looks \"rational\", with expansion in blood-collection centres, inventory and capacity in line with demand, providing further upside for CSL** Jefferies maintains \"buy\" call for CSL, price target of A$240** CSL fell 38.7% last year  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL4N3YT2G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2607746337","title":"Assessing CSL (ASX:CSL) Valuation As Half Year Results And Seqirus Uncertainty Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2607746337","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607746337?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:29","pubTimestamp":1769606953,"startTime":"0","endTime":"0","summary":"Investors are eyeing CSL (ASX:CSL) ahead of its February 11 half year results, with last year's profit guidance downgrade, the delayed Seqirus spin off and weaker US flu vaccinations still shaping sentiment.\nSee our latest analysis for CSL.\nCSL shares recently saw a 1-day share price return of a 1.15% decline to A$180.19. However, the 7-day and 30-day share price returns of 2.32% and 3.83% suggest some near term momentum after a weak year, with a 1-year total shareholder return of a 33.75%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-as-half-year-results-and-seqi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-as-half-year-results-and-seqi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7511","BK7508","CSL.AU","BK4086","BK7501","CSL","LU0728928796.USD","LU1169590202.USD","SG9999004303.SGD","SGXZ23171101.USD","BK7067","LU1169589451.USD"],"gpt_icon":0},{"id":"2606245946","title":"The Bull Case For Carlisle Companies (CSL) Could Change Following Its Vision 2030 Acquisition Drive – Learn Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2606245946","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606245946?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:16","pubTimestamp":1769426195,"startTime":"0","endTime":"0","summary":"Carlisle Companies has been advancing its Vision 2030 strategy, using acquisitions in metal systems, insulation, and recycled materials to expand its building solutions portfolio and support energy-efficient construction demand in recent years.\nAn interesting angle is how Carlisle’s focus on operational excellence and disciplined capital allocation under Vision 2030 connects product innovation directly with long-term shareholder returns.\nNext, we’ll examine how the Vision 2030 growth...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/the-bull-case-for-carlisle-companies-csl-could-change-follow","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/the-bull-case-for-carlisle-companies-csl-could-change-follow","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK4086","BK7067","BK7508","LU1169590202.USD","CSL.AU","BK7511","SG9999004303.SGD","LU0728928796.USD","SGXZ23171101.USD","CSL","LU1169589451.USD"],"gpt_icon":0},{"id":"2605168441","title":"How Investors May Respond To CSL (ASX:CSL) After RBC Upgrade Amid Seqirus Spin-Off Pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2605168441","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605168441?lang=en_us&edition=fundamental","pubTime":"2026-01-23 03:44","pubTimestamp":1769111058,"startTime":"0","endTime":"0","summary":"RBC Capital recently upgraded CSL to Outperform, arguing that the recent selloff and upcoming February half-year results create a compelling opportunity despite sector headwinds.\nThe shift in analyst stance comes as investors reassess CSL’s credibility after it cut its fiscal 2026 growth outlook and paused the planned Seqirus vaccines spin-off.\nNext, we’ll examine how this upgrade, set against weaker flu vaccine demand and Seqirus uncertainty, shapes CSL’s investment narrative.\nWe've found...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-after-rbc-upgrade-am","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-after-rbc-upgrade-am","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","CSL.AU","CSL"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":198,"code":"91000000","status":"200"}]}}